SEC Form 4 research
| Issuer | Xeris Biopharma Holdings, Inc. |
|---|---|
| Tickers | XERS |
| Reporting owners | 19 |
| Officers and directors | 13 |
| Last public filing | 2026-11-06 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-11-06 | 2026-11-05 | McCulloch Kevin | S | 25,000 | $12.49 | Not reported |
| 2026-11-04 | 2026-11-02 | Pieper Steven | S | 5,000 | $10.23 | Not reported |
| 2026-11-04 | 2026-11-02 | Hecht Beth | S | 25,000 | $10.23 | Not reported |
| 2026-11-04 | 2026-11-02 | McCulloch Kevin | S | 15,000 | $10.23 | Not reported |
| 2026-11-04 | 2026-11-02 | Taddese Menassie | A | 22,365 | $0 | Not reported |
| 2026-10-02 | 2026-10-01 | Pieper Steven | S | 5,000 | $9.41 | Not reported |
| 2026-10-02 | 2026-10-01 | McCulloch Kevin | S | 15,000 | $9.41 | Not reported |
| 2026-10-02 | 2026-10-01 | Hecht Beth | S | 16,666 | $9.41 | Not reported |
| 2026-09-29 | 2026-09-28 | McCulloch Kevin | S | 25,000 | $10 | Not reported |
| 2026-09-01 | 2026-09-01 | McCulloch Kevin | S | 15,000 | $8.49 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.